PLRZ (polyrizon-biotech.com) Market Value to Book Value Ratio

Polyrizon Ltd (PLRZ) is developing the Capture and Confine nasal barrier system to block pathogens. The price-to-book ratio visualizes asset value dynamics, where 0.77 indicates the level of this metric. However, geopolitics complicates raw material logistics and patent protection. The company's environmental profile remains neutral, relying on standard biomaterial disposal.

Market Capitalization to Net Assets: polyrizon-biotech.com (PLRZ) for 10/30/2024 - 10/27/2026

The metric is calculated as the quotient of the total market capitalization divided by the net asset value. It determines the degree of business overvaluation relative to its actual tangible resources. For Polyrizon Ltd (PLRZ), this gap is driven by expectations regarding the commercialization of nasal sprays and a reliance on grants. Investors should evaluate the price-to-book ratio as an indicator of speculative potential. High values on this chart signal risks of a correction.

Direct competitors

Market Cap to Net Assets Ratio Vertex Pharmaceuticals (VRTX)|ALNY (alnylam.com) - Market Capitalization to Net Assets|INSM: Market Value to Book Value Ratio|Market Capitalization to Book Value UTHR|BMRN - Market Value to Book Value Ratio|Market Capitalization to Net Assets BridgeBio Corp (BBIO)|BGM: Market Capitalization to Book Value Ratio|Market-to-Book Ratio cogentbio.com COGT|XERS: Market Capitalization to Book Value Ratio|KROS - Market Cap to Net Assets Ratio|Arcturus Pharma - Market Capitalization to Book Value Ratio|Eton Corp (ETON) - Market Capitalization to Book Value|KMDA (Kamada Ltd.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio FULC|Market Value to Book Value Ratio Abeona Therapeutics (ABEO)|Market Value to Book Value Ratio mereobiopharma.com (MREO)|Market Capitalization to Book Value Ratio PLX|PLRX - Market Capitalization to Book Value|Market Cap to Net Assets Ratio Applied Therapeutics|RNTX - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio GELS|Aytu BioPharma (AYTU) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Chemomab Therapeutics Ltd (CMMB)|Capitalization to Book Value Ratio SRx Health (SRXH)|Aeterna Zentaris (AEZS) - Market Cap to Net Assets Ratio|Market Value to Book Value CYTH (cyclotherapeutics.com)|Inozyme Pharma (INZY) - Market Value to Book Value Ratio|Market Capitalization to Net Assets Reneo Pharmaceuticals Inc. RPHM|Market Capitalization to Book Value Ratio Aeterna Zentaris (CSCI)